Related Experiment Video
Updated: Jan 9, 2026
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
Exploring the Therapeutic Potential of Antidiabetic Drugs in Cardiac Arrhythmia Management: A Drug Target Mendelian
Zheng-Qi Song1,2, Zhi-Bo Zhou3, Bo-Xiang Wang3
1Donghai County People's Hospital - Jiangnan University Smart Healthcare Joint Laboratory Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University) Lianyungang City Jiangsu Province China.
Insights
Several antidiabetic drug targets show potential for managing cardiac arrhythmias. Sulfonylurea, SGLT2 inhibitors, and TZDs were linked to reduced risks of specific arrhythmias like paroxysmal tachycardia and atrial fibrillation.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Endocrinology
Background:
- Cardiac arrhythmias represent a significant global health burden.
- The intricate relationship between antidiabetic medications and cardiac arrhythmia risk remains incompletely elucidated.
- Understanding these associations is crucial for optimizing patient care and developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential causal links between antidiabetic drug targets and the risk of developing five distinct cardiac arrhythmias.
- To explore the role of gene expression of antidiabetic drug targets in the context of cardiac arrhythmias.
Main Methods:
- A two-sample Mendelian Randomization (MR) analysis was performed using genetic instruments for hemoglobin A1c (HbA1c) as proxies for antidiabetic drug targets.
- Data on five cardiac arrhythmias were obtained from the Finngen database.
- Summary-data-based Mendelian randomization (SMR) analysis, utilizing eQTLgen consortium gene expression data, was employed to assess gene expression-level effects.
Main Results:
- Significant associations were identified: sulfonylurea targets (KCNJ11/ABCC8) with reduced paroxysmal tachycardia risk (OR: 0.69).
- Sodium-glucose cotransporter 2 inhibitor (SGLT2i) target (SLC5A2) showed a link to decreased right bundle branch block risk (OR: 0.85).
- Thiazolidinediones (TZDs) target (RXRB) was associated with lower atrial fibrillation occurrence (OR: 0.88). SMR analysis confirmed KCNJ11's role in paroxysmal tachycardia.
Conclusions:
- The study suggests that specific antidiabetic drug targets may hold therapeutic potential for managing cardiac arrhythmias.
- These findings highlight potential avenues for drug repurposing and the development of novel treatments for cardiac rhythm disorders.
- Further research is warranted to validate these associations and explore clinical applications.
Background:
Cardiac arrhythmias pose a major health concern while the role of antidiabetic medications in cardiac arrhythmic risks is not fully understood.
Method:
We conducted a two-sample Mendelian Randomization (MR) analysis using genetic instruments extracted from hemoglobin A1C (HbA1c) as proxies for antidiabetic drug targets to evaluate their causal relationship with five cardiac arrhythmias derived from the Finngen database. Summary-data-based Mendelian randomization (SMR) utilizing gene expression data from the eQTLgen consortium was further employed to assess the role of antidiabetic drug targets in cardiac arrhythmias from the gene expression perspective.
Results:
Three significant associations were identified. Sulfonylurea targets KCNJ11/ABCC8 were associated with a decreased incidence of paroxysmal tachycardia (OR: 0.69, 95% CI: 0.56, 0.86, P FDR = 0.022). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) target SLC5A2 was linked to a reduced risk of right bundle branch block (OR: 0.85, 95% CI: 0.77, 0.94, PFDR = 0.022), and thiazolidinediones (TZDs) targeting RXRB were associated with a lowered atrial fibrillation occurrence (OR: 0.88, 95% CI: 0.82, 0.94, P FDR = 0.019). No significant relationships were found between any antidiabetic drug targets and left bundle branch block or atrioventricular block. SMR analysis indicated that lowered expression of KCNJ11 was related to a decreased paroxysmal tachycardia risk (OR: 1.05, 95% CI: 1.01, 1.08, P SMR = 0.010), further confirming the role of KCNJ11 in paroxysmal tachycardia.
Conclusion:
Our findings suggest that several antidiabetic drug targets may have potential therapeutic applications in the management of cardiac arrhythmias.
More Related Videos
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents
01:25Dysrhythmias VI: Management of Dysrhythmias